中文
FROM CRITICAL EQUIPMENT TO
TOTAL PROCESS SOLUTION
Invitation | Pharmadule Morimatsu AB invites you to attend ISPE Europe Annual Conference & BPI Europe
Time:2023-05-09 09:33:50

ISPE Europe Annual Conference

ISPE Europe-signature.png

Conference Name

ISPE Europe Annual Conference

Time

8 - 10 May

Venue

Amsterdam, The Netherlands

Booth

113

2023 ISPE Europe Annual Conference draws pharmaceutical and biopharmaceutical professionals at all levels of the industry - from students and emerging leaders to the most senior executives in drug manufacturing, supply chain, devices, equipment and services, and global regulatory agencies.


BioProcess International Europe

BPI-signature.png

Conference Name

BioProcess International Europe

Time

9-12 May

Venue

RAI in Amsterdam

Booth

49

BioProcess International Europe is an annual conference that brings together experts, scientists and industry leaders from the global biopharmaceutical industry to provide a platform to explore the latest technologies, trends and challenges in bioprocessing, manufacturing and commercialization. It is designed to help accelerate the development and commercialization of the next generation of biologics and cell therapy products.

About Pharmadule Morimatsu AB

Pharmadule, a globally recognized leader in modular plant and solutions provision, has proudly completed 80 production facilities within the pharmaceutical and biopharmaceutical industries, along with over 300 successful engineering design and validation solutions since its establishment in 1986. With extensive experience in international project delivery and proper understanding of regulatory requirements in different regions, Pharmadule continues to provide a range of engineering and solutions to pharmaceutical and biopharmaceutical clients worldwide. After becoming a member of Morimatsu Group in 2011, Pharmadule Morimatsu AB perfectly integrates modular plants with process thanks to the strong combination, allowing the company to provide clients with higher-quality and faster turnkey solutions. Pharmadule Morimatsu AB has been selected by globally recognized pharmaceutical clients including Eli Lily, Merck, Baxter, GSK, Genentech, AZ and Lonza, to facilitate quicker and more efficient patient treatment plans.

 

Pharmadule Morimatsu AB will present new project cases and solutions at the exhibition. The company will have an exchange of views with industry professionals on new developments in digital and intelligent turnkey plant solutions, modular facilities, process systems, bioreactors and other products. Look forward to seeing you there!

About Morimatsu Life Science

Morimatsu Life Science is the sanitary business segment of Morimatsu International Holding Co., Ltd. (Morimatsu International, stock code: 2155.HK), covering industries such as pharmaceuticals, biopharmaceuticals, FMCG, cosmetic and electronic chemicals, and mainly includes Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) Life Technology Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Pharmadule Morimatsu AB (Sweden) and other companies and their affiliates, focusing on the R&D, manufacturing and sales of products in related fields.

Morimatsu, founded in Japan and taken root in China, has developed into a multi-national company that embraces globalization, masters core technology, and gains rich experience from project implementation in diverse fields including core equipment, process systems, and engineering solutions. Starting from its advanced manufacturing base in China, Morimatsu International has opened subsidiaries or plants in Sweden, the United States, India, Italy, Malaysia and Singapore, and has delivered different forms of products and services to more than 40 countries and regions so far, by virtue of its global footprint of efficient and professional team.

Forward-Looking Statements

The information in this press release may include some forward-looking statements. Such statements are essentially susceptible to considerable risks and uncertainties. The use of “predicted”, “believed”, “forecast”, “planned” and/or other similar words/phrases in all statements related to our company is to indicate that the statements are forward-looking ones. Our company undertakes no obligation to constantly revise such predicted statements.

Forward-looking statements are based on our company management’s current perspectives, assumptions, expectations, estimations, predictions and understanding of future affairs at the time of the making of such statements. Such statements are not guaranties of future development and are susceptible to the impact of risks, uncertainties and other factors; some are beyond the control of our company and unpredictable. Subject to the influence of future changes and development in our business, competition environment, political, economic, legal and social conditions, the actual outcomes may differ significantly from the information contained in the forward-looking statements.